Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 18;25(22):5389.
doi: 10.3390/molecules25225389.

Curcumin Formulations and Trials: What's New in Neurological Diseases

Stella Gagliardi  1 , Carlo Morasso  2 , Polychronis Stivaktakis  3 , Cecilia Pandini  1   4 , Veronica Tinelli  2 , Aristides Tsatsakis  3 , Davide Prosperi  2   5 , Miriam Hickey  6 , Fabio Corsi  2   7 , Cristina Cereda  1
Affiliations
Review

Curcumin Formulations and Trials: What's New in Neurological Diseases

Stella Gagliardi et al. Molecules. .

Abstract

Curcumin's pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin's main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline.

Keywords: clinical trials; curcumin; nanoformulation; neurological diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Burapan S., Kim M., Paisooksantivatana Y., Eser B.E., Han J. Thai Curcuma Species: Antioxidant and Bioactive Compounds. Foods. 2020;9:1219. doi: 10.3390/foods9091219. - DOI - PMC - PubMed
    1. Shishodia S. Molecular mechanisms of curcumin action: Gene expression. Biofactors. 2013;39:37–55. doi: 10.1002/biof.1041. - DOI - PubMed
    1. Veena V., Harikrishnan A., Khanna S. Design of new improved curcumin derivatives to multi-targets of cancer and inflammation. Curr. Drug Targets. 2020 doi: 10.2174/1389450121666200804113745. - DOI - PubMed
    1. Joe B., Vijaykumar M., Lokesh B.R. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit. Rev. Food Sci. Nutr. 2004;44:97–111. doi: 10.1080/10408690490424702. - DOI - PubMed
    1. Jaroonwitchawan T., Chaicharoenaudomrung N., Namkaew J., Noisa P. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy. Neurosci. Lett. 2017;636:40–47. doi: 10.1016/j.neulet.2016.10.050. - DOI - PubMed

Grants and funding